Heat Intolerance in the Group of FMF Patients
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
There now causation between Heat Intolerance and FMF that were showed in studies till now. We suggest that the prevalence of Heat Intolerance in the group of the FMF patients will be significantly higher than in the group of healthy individuals, that participated in the study of Heller Institute of Medical Research. The aim of the study is verification of causation between these pathologies. The information obtained by the study may allow us to determine the sequence of events associated with FMF attack development, and perhaps take us one step further in the understanding of the pathogenesis of the disease.
15 FMF patients with double mutations MEFV, mail sex, from the age from 18 to 30 without attacks during not less than 2 month will participate in the study. To identify an individuals susceptibility to exercise heat test, a Heat Tolerance Test (HTT) will perform, according to HTT Protocol of Heller Institute of Medical Research.
| Condition |
|---|
|
Familial Mediterranean Fever Heat Intolerance Heat Tolerance Test |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Heat Intolerance in the Group of FMF Patients |
| Estimated Enrollment: | 15 |
| Study Start Date: | December 2009 |
| Estimated Study Completion Date: | April 2010 |
| Estimated Primary Completion Date: | February 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
FMF patients
15 FMF patients with double mutations MEFV, mail sex, from the age from 18 to 30. treated with colchicine, without attacks not less than 2 months
|
|
healthy people
Healthy individuals, that participated in the study of Heller Institute of Medical Research.
|
Detailed Description:
Familial Mediterranean fever (FMF) is a genetic disease, caused by mutations in the FMF gene, entitled MEFV. The disease is characterized by painful attacks of inflammation in sites lined by serous membranes (e.g. abdominal pain caused by inflammation of the peritoneum, a serous membrane surrounding all internal organs within the abdomen, fever during the attack. Continuous colchicine treatment prevents attacks in most patients. The pathogenesis of the disease, what leads to the attacks, is the questions not yet resolved. We know that there is correlation between protein Pyrin and activity of Interleukin 1 (IL1).
Tolerance to sustain heat stress varies due to individual variation. Under extreme conditions of exercise-heat stress, even healthy, well acclimated, physically fit individuals will ultimately store heat at the rate that will cause body temperature to rise. Individuals who are not able to sustain heat and whose body temperature will start rising earlier and at a higher rate than that of others, under the same conditions, are defined as "heat intolerant".
There now causation between Heat Intolerance and FMF that were showed in studies till now. We suggest that the prevalence of Heat Intolerance in the group of the FMF patients will be significantly higher than in the group of healthy individuals, that participated in the study of Heller Institute of Medical Research. The aim of the study is verification of causation between these pathologies. The information obtained by the study may allow us to determine the sequence of events associated with FMF attack development, and perhaps take us one step further in the understanding of the pathogenesis of the disease.
15 FMF patients with double mutations MEFV, mail sex, from the age from 18 to 30 without attacks during not less than 2 month will participate in the study. To identify an individuals susceptibility to exercise heat test, a Heat Tolerance Test (HTT) will perform, according to HTT Protocol of Heller Institute of Medical Research.
Eligibility| Ages Eligible for Study: | 18 Years to 30 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
15 FMF patients with double mutations MEFV, mail sex, from the age from 18 to 30. treated with colchicine, without attacks not less than 2 months
Inclusion Criteria:
- double mutations MEFV
- age from 18 to 30
- colchicine treatment
- absence of attack during 2 months
Exclusion Criteria:
- individual wish
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Avi Livneh, Sheba Medical Center, Department of Internal Medicine |
| ClinicalTrials.gov Identifier: | NCT01059279 History of Changes |
| Other Study ID Numbers: | SHEBA-09-7575-AL-CTIL |
| Study First Received: | January 28, 2010 |
| Last Updated: | January 28, 2010 |
| Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
Keywords provided by Sheba Medical Center:
|
Familial Mediterranean fever Cytokines Inflammatory proteins MEFV |
mutations Heat Intolerance Heat Tolerance Test |
Additional relevant MeSH terms:
|
Familial Mediterranean Fever Hereditary Autoinflammatory Diseases Brucellosis Fever Gram-Negative Bacterial Infections Bacterial Infections |
Body Temperature Changes Signs and Symptoms Genetic Diseases, Inborn Skin Diseases, Genetic Skin Diseases |
ClinicalTrials.gov processed this record on May 19, 2013